The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma

References

• American Cancer Society. Cancer facts & figures 2016. Atlanta, GA: American Cancer Society; 2016.
   Google Scholar
• Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. 2011;8:85–96. doi:10.1038/nrclinonc.2010.189.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732. doi:10.1182/blood-2005-01-0016.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242. doi:10.1056/NEJMoa011795.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391. doi:10.1016/S1470-2045(06)70664-7.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223. doi:10.1056/NEJMoa1400376.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516. doi:10.1056/NEJMoa1306220.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007. doi:10.1056/NEJMoa1315226.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018. doi:10.1056/NEJMoa1314583.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374:311–322. doi:10.1056/NEJMoa1513257.
   PubMed Web of Science ®Google Scholar
• Ozegowski W, Krebs D. IMET 3393, (-[1-Methyl-5-bis-(β-chloroethyl)-amino-benzimidazolyl-(2)]-butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds. Zbl Pharm. 1971;110:1013–1019.
   Google Scholar
• Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309–317. doi:10.1158/1078-0432.CCR-07-1061
   PubMed Web of Science ®Google Scholar
• Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs. 1996;7:415–421.
   PubMed Web of Science ®Google Scholar
• Chow KU, Boehrer S, Geduldig K, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica. 2001;86:485–493.
   PubMed Web of Science ®Google Scholar
• Visco C, Castegnaro S, Chieregato K, et al. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis. 2012;48:68–75. doi:10.1016/j.bcmd.2011.09.007.
   PubMed Web of Science ®Google Scholar
• Castegnaro S, Visco C, Chieregato K, et al. Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. Leuk Lymphoma. 2012;53:2262–2268. doi:10.3109/10428194.2012.688200.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Chow KU, Hoelzer D, et al. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol. 2002;29:12–14.
   PubMed Web of Science ®Google Scholar
• Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002;87:33–43.
   PubMed Web of Science ®Google Scholar
• Preiss R, Sohr R, Matthias M, et al. [The pharmacokinetics of bendamustine (Cytostasane) in humans]. Pharmazie. 1985;40:782–784.
   PubMed Web of Science ®Google Scholar
• Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol. 2007;59:759–770. doi:10.1007/s00280-006-0331-5.
   PubMed Web of Science ®Google Scholar
• Weber H, Amlacher R, Preiss R, et al. [Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice]. Pharmazie. 1991;46:589–591.
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Rosing H, Darwish M, et al. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Drugs R D. 2013;13:17–28. doi:10.1007/s40268-012-0001-5.
   PubMedGoogle Scholar
• Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol. 2010;66:1039–1049. doi:10.1007/s00280-010-1254-8.
   PubMed Web of Science ®Google Scholar
• Ogura M, Uchida T, Taniwaki M, et al. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101:2054–2058. doi:10.1111/j.1349-7006.2010.01633.x.
   PubMed Web of Science ®Google Scholar
• Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin’s-lymphomas. J Cancer Res Clin Oncol. 2002;128:603–609. doi:10.1007/s00432-002-0378-6.
   PubMed Web of Science ®Google Scholar
• Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin’s lymphomas. Anticancer Drugs. 2001;12:725–729.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204–210. doi:10.1200/JCO.2007.12.5070.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106–114. doi:10.1002/cncr.24714.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:3383–3389. doi:10.1200/JCO.2005.08.100.
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4473–4479. doi:10.1200/JCO.2008.17.0001.
   PubMed Web of Science ®Google Scholar
• Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17:57–66. doi:10.1016/S1470-2045(15)00447-7
   PubMed Web of Science ®Google Scholar
• Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442–1449. doi:10.1200/JCO.2012.45.9842.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210. doi:10.1016/S0140-6736(12)61763-2
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944–2952. doi:10.1182/blood-2013-11-531327.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51. doi:10.1016/S0140-6736(10)62175-7.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–531. doi:10.1056/NEJMoa1200920.
   PubMed Web of Science ®Google Scholar
• Rummel M, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of StiL NHL7-2008 MAINTAIN trial). Abstract 7503, ASCO annual meeting 2016
   Google Scholar
• Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2002;13:1285–1289.
   PubMed Web of Science ®Google Scholar
• Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31:2103–2109. doi:10.1200/JCO.2012.46.5203.
   PubMed Web of Science ®Google Scholar
• Park SI, Grover NS, Olajide O, et al. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol. 2016. [published online 2016 July 22]. doi:10.1111/bjh.14232.
   Google Scholar
• Garcia Munoz R, Izquierdo-Gil A, Munoz A, et al. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol. 2014;93:1879–1887. doi:10.1007/s00277-014-2135-8.
   PubMed Web of Science ®Google Scholar
• Saito H, Maruyama D, Maeshima AM, et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J. 2015;5:e362. doi:10.1038/bcj.2015.86.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Christian B, Jaglowski S, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;125:242–248. doi:10.1182/blood-2014-08-597914.
   PubMed Web of Science ®Google Scholar
• Albertsson-Lindblad A, Kolstad A, Laurell A, et al. Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4. Blood. 2016 published online 2016 June.27; pii: blood-2016-03-704023.
   PubMed Web of Science ®Google Scholar
• Zaja F, Ferrero S, Stelitano C, et al. Rituximab, lenalidomide, bendamustine second line therapy in mantle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL). Abstract 014. 13th International Conference on Malignant Lymphoma ICML2015
   Google Scholar
• Weide R, Feiten S, Friesenhahn V, et al. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Leuk Lymphoma. 2013;54:1640–1646. doi:10.3109/10428194.2012.747679.
   PubMed Web of Science ®Google Scholar